The effect of antiretroviral combination treatment on Epstein-Barr virus (EBV) genome load in HIV-infected patients

Viruses

Volumn 2, Issue 4, 2010, Pages 867-879

  Friis, Anna M C ^a   Gyllensten, Katarina ^b   Aleman, Anna ^a   Ernberg, Ingemar ^a   Åkerlund, Börje ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiretroviral treatment; Epstein barr virus; HIV 1; Host virus relationship

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MALE; PERIPHERAL LYMPHOCYTE; TREATMENT DURATION; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952170323     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2040867     Document Type: Article

References (38)

1. Ernberg, I. The role of Epstein-Barr virus in lymphomas of homosexual males. Prog. Allergy. 1986, 37, 301-318.
2. Gaidano, G.; Dalla-Favera, R. Molecular pathogenesis of AIDS-related lymphomas. Adv. Cancer Res. 1995, 67, 113-153.
3. Gerritsen, E.J.; Stam, E.D.; Hermans, J.; van den Berg, H.; Haraldsson, A.; van Tol, M.J.; van den Bergh, R.L.; Waaijer, J.L.; Kroes, A.C.; Kluin, P.M.; Vossen, J.M. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Mar. Transpl. 1996, 18, 377-382.
4. Lucas, K.G.; Small, T.N.; Heller, G.; Dupont, B.; O'Reilly, R.J. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87, 2594-2603.
5. MacMahon, E.M.E.; Glass, J.D.; Hayward, S.B.; Mann, R.B.; Becker, P.S.; Charache, P.; McArthur, J.C.; Armbinder, R.F. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991, 338, 969-973.
6. Camilleri-Broët, S.; Davi, F.; Feuillard, J.; Bourgeois, C.; Seilhean, D.; Hauw, J.J.; Raphaël, M. High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood 1995, 86, 432-435.
7. Hamilton-Dutoit, S.J.; Pallesen, G.; Franzmann, M.B.; Karkov, J.; Black, F.; Skinhoj, P.; Pedersen, C. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am. J. Pathol. 1991, 138, 149-163.
8. Matsuura, A. The latent Epstein.Barr virus (EBV) activation and EBV-specific immunological abnormality in human immunodeficiency virus (HIV) infected hemophiliacs. Hokkaido Igaku Zasshi 1989, 64, 474-483.
9. Palmieri C.; Treibel T.; Large O; Bower M. AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM 2006; 99, 811-826.
10. van Baarle, D.; Kostense, S.; Hovenkamp, E.; Ogg, G.; Nanlohy, N.; Callan, M.F.; Dukers, N.H.; McMichael, A.J.; van Oers, M.H.; Miedema, F. Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection. AIDS 2002 16, 2001-2011.
11. Sandström, E.; Wahren, B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999, 353, 1735-1742.
12. Herndier, B.G.; Kaplan, L.D.; McGrath, M.S. Pathogenesis of AIDS lymphomas. AIDS 1994, 8, 1025-1049.
13. Lyter, D.; Besley, D.; Thackeray, R.; et al, Incidence of malignancies in the Multicenter AIDS cohort study (MACS). Proc. ASCO 1994, 13, 50, Abstr. 2.
14. Leng, Q.; Borkow, G.; Weisman, Z.; Stein, M.; Kalinkovich, A.; Bentwich, Z., Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. AIDS 2001, 27, 389-397.
15. Grulich, A.E.; Wan, X.; Law, M.G.; Milliken, S.T.; Lewis, C.R.; Garsia, R.J.; Gold, J.; Finlayson, R.J.; Cooper, D.A.; Kaldor, J.M., B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000, 14, 133-140.
16. Rooney, C.M.; Loftin, S.K.; Holladay, M.S.; Brenner, M.K.; Krance, R.A.; Heslop, H.E., Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br. J. Haematol. 1995, 89, 98-103.
17. Lucas, K.G.; Burton, R.L.; Zimmerman, S.E.; Wang, J.; Cornetta, K.G.; Robertson, K.A.; Lee, C.H.; Emanuel, D.J., Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998, 91, 3654-3661.
18. Bakker, N.; Verschuuren, E.; Erasmus, M.; Hepkema, B.; Veeger, N.; Kallenberg, C.; van der Bij, W., Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007, 83, 433-438.
19. Bonnet, F.; Chêne, G., Evolving epidemiology of malignancies in HIV. Curr. Opin. Oncol. 2008, 20, 534-540.
20. Righetta, E.; Ballon, G.; Ometto, L.; Cattelan, A.M.; Menin, C.; Zanchetta, M.; Chieco-Bianchi, L.; De Rosa, A., Dynamics of Epstein-Barr virus in HIV-1 infected subjects on highly active antiretroviral therapy. AIDS 2002, 16, 63-73.
21. Cooney, E.L. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin. Inf. Dis. 2002, 34, 224-233.
22. Bower, M.; Fisher, M.; Hill, T.; Reeves, I; Walsh, J; Orkin, C; Phillips, A.N.; Bansi, L.; Gilson, R.; Easterbrook, P,; Johnson, M.; Gazzard, B.; Leen, C.; Pillay, D.; Schwenk, A.; Anderson, J.; Porter, K.; Gompels, M.; Sabin, C.A. for the UK CHIC Steering Committee. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica, 2009, 94: 875-880.
23. Engels, E.A.; Pfeiffer, R.M.; Landgren, O.; Moore, R.D. Immunologic and Virologic Predictors of AIDS-Related Non-Hodgkin Lymphoma in the Highly Active Antiretroviral Therapy Era. J. Acquir. Immune. Defic. Syndr. In Press.
24. Starzl, T.; Nalesnik, M.; Porter, K.; Ho, M.; Iwatsuki, S.; Griffith, B.; Rosenthal, J.; Hakala, T.; Shaw, B.; Hardesty, R., Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1, 583-587.
25. Pirsch, J.D.; Stratta, R.J.; Sollinger, H.W.; Hafez, G.R.; D'Alessandro, A.M.; Kalayoglu, M.; Belzer, F.O., Treatment of severe Epstien-Barr virus-induced lymphoproliferative syndrome with Ganciclovir: Two cases after solid organ transplantation. Am. J. Med. 1989, 86, 241-244.
26. Pietersma, F.; Piriou, E.; van Baarle, D., Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk Lymphoma. 2008, 6,1028-1041.
27. van Baarle, D.; Wolthers, K.C.; Hovenkamp, E.; Niesters, H.G.M.; Osterhaus, A.D.M.E.; Miedema, F.; van Oers, M.H.J. Absolute Level of Epstein-Barr Virus DNA in Human Immunodeficiency Virus Type 1 Infection Is Not Predictive of AIDS-Related Non-Hodgkin Lymphoma. J. Inf. Dis. 2002, 186, 405-409.
28. Stevens, S.J.C.; Blank, B.S.N.; Smits, P.H.M.; Meenhorst, P.L.; Middeldorp, J.M., High Epstein-Barr virus (EBV) DNA load in HIV-infected patient: correlation with antiretroviral therapy and quantitative EBV serology. AIDS 2002, 16, 993-1001.
29. Ehlin-Henriksson, B.; Zou, J.Z.; Klein, G.; Ernberg, I., Epstein-Barr virus genomes are found predominantly in IgA-positive B cells in the blood of healthy carriers. Int. J. Cancer. 1999, 85, 50-54.
30. Albert, J.; Fenyö, E.M., Simple, sensitive and specific detection of HIV-1 in clinical specimens by polymerase chain reaction with nested primers. J Clin. Microbiol. 1990, 28, 1560-1564.
31. Gustafsson, A.; Levitsky, V.; Zou, J.Z.; Frisan, T.; Dalianis, T.; Ljungman, P.; Ringden, O.; Winiarski, J.; Ernberg, I.; Masucci, M.G., Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000, 95, 807-814.
32. Svahn, A.; Magnusson, M.; Jagdahl, L.; Schloss, L.; Kahlmeter, G.; Linde, A., Evaluation of three commercial enzyme-linked immunosorbent assays and two for diagnosis of primary Epstein-Barr virus infection. J. Clin. Microbiol. 1997, 35, 2728-3272.
33. Reed, L.J.; Muench, H., A simple method of estimating fifty per cent endpoints. An. J. Hyg. 1938, 27, 493-497.
34. Waldman, H.; Cobbold, S.; Lefkovits, I. Limitid dilution analysis. In Lymphocytes: a Practical Approach; Klaus, G.G.B., Ed.; IRL Press Oxford: Oxford, UK, 1987; pp. 163-188.
35. Gérard, L.; Meignin, V.; Galicier, L.; Fieschi, C.; Leturque, N.; Piketty, C.; Fonquernie, L.; Agbalika, F.; Oksenhendler, E. Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication. AIDS 2009, 23, 2301-2308.
36. Kostense, S.; Otto, S.A.; Knol, G.J.; Manting, E.H.; Nanloh, N.M.; Jansen, C.; Lange, J.M.; van Oers, M.H.; Miedema, F.; van Baarle, D. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8+ T cells during highly active antiretroviral therapy is associated with an increase in CD4+ T cells. Eur. J. Immunol. 2002, 32, 1080-1089.
37. Kaufmann, G.R.; Bloch, M.; Finlayson, R.; Zaunders, J.; Smith, D.; Cooper, D.A. The extent of HIV-1 related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2002, 16, 359-367.
38. van Esser, J.W.J.; Niesters H.G.M.; van der Holt, B; Meijer, E.; Osterhaus, A.D.M.E.; Gratama, J.W.; Verdonck, L.F.; Löwenberg, B.; Cornelissen, J.J. Prevention of Epstein-Barr virus- lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99, 4364-4369